Investor FAQs

Investor FAQs

Headquarters

Akero Therapeutics


601 Gateway Boulevard, Suite 350
South San Francisco, CA 94080
Our common stock is traded on the NASDAQ Global Select Market under the ticker symbol, AKRO.
Our initial public offering took place on June 19, 2019.
We do not expect to pay any cash or other dividends on our common stock neither now nor in the foreseeable future.
Communication regarding transfer requirements, lost certificates and changes of address should be directed to:

Computershare Trust Company, N.A.
www.computershare.com
Our legal counsel is:
Goodwin Procter LLP

Our independent auditor is:
Deloitte & Touche LLP
Our quarterly and annual reports, as well as other SEC filings, can be found on the Financials & Filings portion of the Investor Relations website or directly from the SEC at www.sec.gov